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systemic treatment. Among the changes of the pathologic 
subtypes of lung cancer, the proportion of adenocarcinoma, 
which has higher instances of driver mutations, is gradually 
increasing. 
Epidermal growth factor receptor (EGFR, ErbB1, HER1) is a 
cell surface receptor from the ErbB receptor family and is one 
of four related receptor tyrosine kinases, along with HER2/c-
neu (ErbB2), HER3 (ErbB3), and HER4 (ErbB4)2. After ligand 
binding, EGFR changes from an inactive monomer to an ac-
tive homodimer. It may also form a heterodimer with another 
member of the ErbB receptor family. EGFR dimerization 
induces intrinsic protein-tyrosine kinase activity that results in 
autophosphorylation of its C-terminal tyrosine residues3,4. Au-
tophosphorylation of EGFR activates downstream signaling 
cascades such as the AKT, mitogen-activated protein kinase 
(MAPK), and JNK pathways, which ultimately leads to DNA 
synthesis, cell cycle progression, and proliferation5. 
Mutation, amplification, or dysregulation of the EGFR fam-
ily is proposed to occur in approximately 30% of epithelial 
cancers. Somatic mutations that lead to EGFR hyperactivation 
are associated with a number of cancers, including NSCLC, 
colorectal cancer, and glioblastoma multiforme6,7. These so-
matic mutations involving the EGFR tyrosine kinase domain 
Introduction
Lung cancer remains a major cause of cancer death world-
wide. In the year 2012, 1,824,701 new lung cancer cases were 
diagnosed, and 1,590,000 patients died of this devastating dis-
ease worldwide1. Non-small cell lung cancer (NSCLC) com-
prises 80%–85% of lung cancers and more than half of NSCLC 
cases are discovered at an advanced stage, which requires 
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(TKD) lead to the persistent activation of its downstream sig-
naling pathways, which results in uncontrolled cell prolifera-
tion8.
EGFR tyrosine kinase inhibitors (TKI) have been widely 
described as being useful for the treatment of lung cancer 
patients with EGFR-TKI–sensitizing mutations, and their use 
has led to a doubling of progression-free survival9-13 and a 
lengthening of overall survival by more than 2 years. However, 
emergence of resistant cancers has become the ultimate rea-
son for treatment failure, which creates new challenges for the 
daily management of patients with EGFR mutations14. In this 
review, we describe the mechanism behind EGFR-TKI resis-
tance and the strategies available for overcoming resistance to 
EGFR-TKI. 
First and Second Generation EGFR-TKI
It is well established that 50%–80% of NSCLC overexpress 
EGFR. Consequently, there have been numerous treatments 
developed using antibodies and small molecules that inhibits 
EGFR. The first generation EGFR-specific inhibitors, gefitinib 
(ZD1839, Iressa) and erlotinib (Tarceva), inhibit EGFR activity 
by reversibly binding to the adenosine triphosphate (ATP)-
binding site in the TKD (Table 1). In the early 2000s, the 
IDEAL I/II study, which recruited previously treated NSCLC 
patients, was performed to compare the efficacy and adverse 
effects between the 250 mg and 500 mg treatments of gefi-
tinib. The researchers found that daily administration of 250 
mg of gefitinib had an 18.4% response rate with a 95% confi-
dence interval, 11.5–27.3. The difference in the response rate 
between 250 mg and 500 mg was not significant. However, the 
250 mg treatment group had a lower frequency of side effects, 
and so the U.S. Food and Drug Administration (U.S. FDA) ap-
proved gefitinib 250 mg daily for the treatment of NSCLC15. 
The subsequent phase III study, ISEL, which compared 
placebo and gefitinib treatment groups in previously treated 
NSCLC patients, failed to demonstrate any survival benefits 
in the gefitinib treatment group. This led to the discontinua-
tion of gefitinib use in the United States16. However, in 2004, 
mutations in the EGFR-TKD were identified and some of the 
patients who had mutations in EGFR-TKD showed an excel-
lent response to the EGFR-TKI8,17. The L858R point mutation 
in exon 21 and deletion mutations in exon 19 that makes up 
the leucine-arginine-glutamine-alanine (LREA) motif (amino 
acids 747 to 750) were identified as key sensitizing muta-
tions that predict a positive response to EGFR-TKI. Following 
these trials, patients with EGFR mutations were recruited for 
further studies, and a response rate of 60%–80%, along with 
a progression-free survival of approximately 10 months18,19. 
These results helped to establish that specific genetic muta-
tions could predict response rate, progression-free survival, 
and survival rate following drug treatment, and they highlight 
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the importance of predictive biomarkers for drug response.
Acquired resistance to the first generation EGFR-TKI had 
accelerated the clinical development of second generation 
EGFR-TKI, which is characterized by irreversible covalent at-
tachments to the EGFR-TKD and additional activity against 
other receptors which belong to EGFR family or structurally 
similar receptors20. Several drugs with these characteristics 
had started clinical trials but most of the second generation 
EGFR-TKI, except afatinib, had failed because of lack of clini-
cal efficacy or limitation of clinical dosing due to toxicity in 
NSCLC. 
EGFR Mutations: Sensitizing vs. Non-
sensitizing EGFR Mutations
Activating EGFR mutations are frequently identified in 
lung adenocarcinoma, and advances in genotyping technol-
ogy has facilitated the discovery of such mutations in small 
size samples21,22. The most frequently detected type of EGFR 
mutation is an in-frame deletion of exon 19 (E19del) near the 
LREA motif that accounts for approximately 45% of mutations 
in the TKD, as well as the L858R point mutation of exon 21 
that accounts for approximately 40% of TKD mutations23-25. In 
addition to E19del and L858R mutations, less frequent muta-
tions, such as point mutations in exon 18 at position G719 
(approximately 3% occurrence rate) and the exon 21 L861Q 
mutant (approximately 2%), are sensitive to EGFR-TKI26-28. On 
the other hand, an in-frame insertion within exon 20 of EGFR, 
which accounts for 4%–10% of all TKD mutations, and other 
rare mutations including L747S, D761Y, T790M, and T854A 
confer resistance to EGFR-TKI29-31. 
As more sensitive and precise tumor genotyping systems 
have been made available for clinical applications, rare EGFR 
mutations of unknown biological and clinical significance 
are frequently encountered in routine practice22. Different 
responses to EGFR-TKI have been reported for mutations 
within the same approximate genomic location. For example, 
in-frame insertions within EGFR exon 20 were originally con-
sidered to confer EGFR-TKI resistance with a low response 
rate (5%) and short interval of disease control; however, A763_
Y764insFQEA has been reported to be a sensitizing mutation 
to EGFR-TKI31. These findings indicate that more attention 
and collaborative efforts are required to elucidate the biologi-
cal and clinical significance of these rare and diverse EGFR 
mutations.
Mechanisms of EGFR-TKI Resistance
Even if EGFR-TKI is administered after confirmation of a 
mutation in the EGFR-TKD, some patients do not respond 
to EGFR-TKI at all (de novo /intrinsic resistance), and the 
remaining patients who had a favorable response at initial 
treatment eventually exhibit disease progression after 10–14 
months (acquired resistance). Several mechanisms regulating 
resistance have been identified, and they may be classified as 
intrinsic and acquired resistance (Figure 1)32.
Intrinsic Resistance to EGFR-TKI
1. BCL2-like 11 intron 2 deletion polymorphism
BCL2-like11 (BIM) is a pro-apoptotic molecule of the BCL2 
family and is required for TKI-induced apoptotic cell death. 
The intron 2 deletion polymorphism of BIM causes a splicing 
switch between exon 4 and exon 3, resulting in a BIM isoform 
variant lacking the pro-apoptotic BCL2-homology 3 (BH3) 
domain. The BH3 domain interacts with other members of 
the BCL2 protein family, including BCL2, BCL2L1/BCL-X(L), 
and MCL1 and inhibits their anti-apoptotic function. The in-
tron 2 deletion polymorphism confers intrinsic TKI resistance 
for NSCLC patients with EGFR mutations, resulting in signifi-
cantly inferior responses33. The BIM  intron 2 deletion poly-
morphism is rare in Western populations but is found in about 
12%–15% of Far East Asian populations. This polymorphism 
does not increase the risk of lung cancer; instead, it limits the 
response to EGFR-TKI33,34.
2. Compound EGFR mutations
Not only have advances in sequencing technology enabled 
researchers to acquire more accurate data, but they have also 
provided a higher probability of identifying a greater number 
of mutations in the EGFR-TKD from smaller samples. Com-
pound EGFR mutations, defined as double or multiple muta-
tions in the EGFR-TKD, are frequently detected with newer 
sequencing technology. A study analyzing 61 cases of EGFR 
mutation-positive lung adenocarcinoma with next-generation 
sequencing (NGS)–based repeated deep sequencing found 
that compound EGFR mutations account for 24.6% of EGFR 
mutation-positive lung adenocarcinoma. The majority of 
compound EGFR mutations are a combination of atypi-
cal mutations and typical mutations, such as E19del and 
L858R22,35. Kobayashi et al.36 showed that compound EGFR 
mutations in which an EGFR-TKI–sensitizing mutation—such 
as G719X, E19del, L858R, or L861Q—coexist with rare muta-
tions of other residues of the TKD that are somewhat sensi-
tive to EGFR-TKI. Peng et al.37 compared the clinical outcome 
between NSCLC patients with L858R single mutation with 
patients harboring both a L858R mutation and a co-mutation 
in EGFR exon 18–21 and found no significant differences in 
overall survival and progression-free survival. Another study 
addressed the clinical significance of compound EGFR muta-
tions and found that patients with rare atypical mutations and 
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either E19del or L858R had a less favorable outcome com-
pared with patients who have a single typical mutation. Com-
pound mutations that contain sensitizing mutations, such as 
G719X or L858R, seem to have favorable responses to EGFR-
TKI. On the other hand, compound mutations consisting of 
rare atypical mutations have a poor response to EGFR-TKI35. 
Taken together, the patients with compound EGFR mutations 
have a shorter overall survival than those with simple muta-
tions and, therefore, they should be closely monitored during 
follow-up. 
3. Co-alteration of other genes
The concept that any given cancer will have a single driver 
mutation is now being challenged by data acquired from 
sequencing multiple genes simultaneously. Although EGFR 
mutations are the only driver mutation in many cases of lung 
adenocarcinoma, driver mutations in other genes are found 
intermittently with advances in sequencing technology. When 
the EGFR mutation status was reassessed with target enriched 
NGS in anaplastic lymphoma kinase (ALK) rearrangement-
positive NSCLCs, the co-mutation rate was found to be as 
high as 15.4%. In this study, authors evaluated the response to 
TKIs in 14 NSCLC patients with EGFR and ALK co-alteration. 
Among them, three were treated with EGFR-TKI and had poor 
responses to gefitinib, whereas the eight treated with ALK 
inhibitors had favorable responses, suggesting that signaling 
from ALK rearrangement may override EGFR38. Another study 
found that mutations in exon 9 and 20 of the PIK3CA gene 
occurred in 3.9% of squamous cell cancers and 2.7% of adeno-
carcinomas. Among 34 NSCLC cases harboring PIK3CA mu-
tations, 17 cases had a co-mutation in EGFR exon 18–21 and 
4 cases had a co-mutation in KRAS exon 2–3, indicating that 
PIK3CA mutations are frequently accompanied by EGFR/
KRAS mutations. These studies revealed the importance of 
identifying PIK3CA mutations by demonstrating that patients 
with PIK3CA single mutation have a poorer prognosis than 
those with co-mutation of PIK3CA and EGFR/KRAS 39.
Acquired Mechanism of Resistance
1. Alteration of EGFR
The T790M gatekeeper mutation, localized in exon 20 of 
EGFR, has been found for the first time to confer resistance 
to EGFR-TKI40 and can be identified in about half of patients 
who experience resistance after treatment with first genera-
tion EGFR-TKI41. This threonine-to-methionine substitution 
leads to an increased affinity of EGFR to ATP compared with 
Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Muta-
tions in the EGFR gene. T790M mutation induces conformational changes on the ATP-binding pocket of EGFR–tyrosine kinase domain, 
inhibiting interaction with the drug target site. (B) Activation of alternative signaling pathways. MET amplification, and overexpression of 
phosphoinositide 3-kinase (PI3K)/AKT, mitogen-activated protein kinase (MAPK), and AXL bypass the dependency on EGFR activation and 
can promote survival and proliferation. (C) Phenotypic changes, small cell lung cancer transformation, and epithelial-mesenchymal transi-
tion (EMT) confer resistance to EGFR-TKI. SCLC: small cell lung cancer.
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its affinity to first generation of EGFR-TKI. The bulkier methio-
nine residue at position 790 sterically inhibits the interaction 
with the inhibitor, effectively preventing its binding to the TKD 
while preserving catalytic activity. The T790M mutation has 
been rarely identified in the EGFR-TKI naïve patients in West-
ern countries42. A few EGFR-TKI–resistant mutations have 
also been identified, such as T854A in exon 21, D761Y, and 
L747S, but their clinical relevance remains unclear43-45. 
Three drugs have been developed for patients with the 
T790M mutation and are ready for clinical application: CO-
1686 (Clovis, Rociletinib), which was first developed specifi-
cally for T790M; AZD9291 (AstraZeneca, Tagrisso, Osimer-
tinib); and BI1482694/HM61713 (Hanmi, Olita, Olmutinib). 
Third generation EGFR mutant selective inhibitors (EMSIs) 
are characterized by sparing wild type EGFR, selective inhibi-
tion of T790M, and irreversible covalent binding to target. A 
brief comparison is available in Table 146. CO-1686 demon-
strated its efficacy in treating T790M-positive NSCLC during 
TIGER-X (Phase 2), TIGER-1 (Phase 2/3), TIGER-2 (Phase 2), 
and TIGER-3 (Phase 3) studies; however, hyperlipidemia, nau-
sea, vomiting, and corrected QT interval prolongation became 
primary concerns. AZD9291 also demonstrated its efficacy 
in treating T790M-positive patients through AURA1, AURA2, 
and FLAURA trails. Although it had less severe adverse effects 
than gefitinib, there were reports of skin rashes, diarrhea, and, 
in some cases, interstitial pneumonitis. AZD9291 was first 
approved by the U.S. FDA for the treatment of EGFR muta-
tion–positive NSCLC among the third generation EMSI and 
is now available in our medical fields. ASP8273 (Astellas) 
and EGF816 (Novartis) were recently developed; however, 
resistance against these third generation EGFR-TKI eventually 
develop, possibly through the C797S mutation. 
Activation of Alternative Pathways
1. MET amplification
MET amplification was first identified in EGFR-TKI–sensi-
tive lung cancer cells that develop resistance after prolonged 
exposure to gefitinib as a result of focal amplification of the 
MET gene. MET amplification was identified in four of 18 lung 
cancers that had developed resistance to EGFR-TKI through 
ErbB3-dependent activation of phosphoinositide 3-kinase 
(PI3K)47. Although the frequency of MET amplification in 
treating naïve NSCLC is rare, MET amplification is the second 
most commonly acquired resistance mechanism, occurring 
up to 20% during EGFR-TKI treatment. Cell lines with MET 
gene amplification are extremely sensitive to MET inhibition, 
and the majority of preclinical and clinical data demonstrate 
that co-inhibition of MET and EGFR may be an effective 
strategy to overcoming resistance. A trial involving use of the 
MET inhibitor onartuzumab in combination with erlotinib in 
heavily treated patients had promising results: MET-positive 
patients assessed by immunohistochemistry had increased 
progression-free survival and overall survival compared with 
MET-negative patients48. Following the METLung phase III 
trial, which compared the combination of onartuzumab and 
erlotinib with erlotinib alone in MET-positive and EGFR mu-
tation-positive patients did not show any differences between 
the groups at interim analysis, and so the trial was terminated 
early. Ficlatuzumab is an anti-MET monoclonal antibody that 
targets the hepatocyte growth factor. In a phase II trial recruit-
ing EGFR  sensitizing mutation-positive Asian patients, the 
combination of ficlatuzumab and gefitinib did not improve 
response rate or progression-free survival. However, a subset 
of patients with EGFR sensitizing mutation positive and MET-
low expression patients benefited from this combination, 
suggesting ficlatuzumab may inhibit emergence of resistant 
clones49. The MARQUEE trial (MET inhibitor ARQ 197 plus 
erlotinib versus erlotinib plus placebo in NSCLC) and ATTEN-
TION trial (Asian trial of tivantinib plus erlotinib versus erlo-
tinib for NSCLC without EGFR mutation) were both phase III 
trials that evaluated tivantinib, a selective MET inhibitor used 
previously to treat unselected patients. Both studies did not 
reveal a difference in overall survival. Cabozantinib (XL184/
BMS-907351; Exelixis/Bristol Myer Squibb), foretinib (XL880, 
EXEL-2880, GSK1363089; Exelixis/GSK), MetMAb (Genen-
tech-Roche), and crizotinib (PF-2341066; Pfizer) have been 
developed as MET inhibitors and are undergoing clinical tri-
als50. Although MET poses as an ideal biological target whose 
amplification is frequently observed in EGFR-TKI treated pa-
tients, its clinical benefit is still modest. 
2. HER2 amplification
HER2 amplification or overexpression is associated with 
more aggressive types of cancer. HER2 amplification is a 
rare event that occurs in 1%–2% of untreated lung adenocar-
cinoma as measured by fluorescence in situ  hybridization 
(FISH), a microarray-based genomic copy number analysis. 
A study that adapted FISH to measure HER2  amplification 
found that 12% of tumors had acquired resistance to EGFR-
TKI, and that this event is mutually exclusive to those with the 
T790M mutation51. Because afatinib is a second generation 
irreversible pan-HER inhibitor, it was expected to be effective 
in the patients previously treated with first generation EGFR-
TKI. LUX-Lung 4 trial, a phase II single-arm study, enrolled 
62 patients that were previously treated with gefitinib and/or 
erlotinib and also with afatinib. Although not all the patients in 
this study harbored HER2 amplification, the effect of afatinib 
was modest and had an overall response rate of 8.2%, and pro-
gression-free survival was found to be 4.4 months52. Based on 
these findings, Takezawa et al.51 suggested that the combina-
tion of afatinib and cetuximab would be beneficial for patients 
without the T790M mutation who experienced acquired 
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resistance after EGFR-TKI treatment. The combination of 
afatinib and cetuximab induces tumor regression by decreas-
ing the phosphorylation of EGFR and total EGFR expression, 
resulting in inhibition of its signaling pathways53. In a phase Ib 
trial that combined cetuximab and afatinib for 126 NSCLC pa-
tients whose disease progressed during EGFR-TKI treatment, 
the overall response rate was 29% and progression-free surviv-
al was 4.7 months. Interestingly, this combination was equally 
effective in T790M-positive and negative patients54, implying 
that the efficacy of the combination is attribute to the intrinsic 
effect of afatinib or associated with any EGFR-TKI combined 
with cetuximab needs to be clarified.
3. PIK3CA mutation
PIK3CA , which encodes the catalytic subunit of PI3K, is 
occasionally mutated in lung cancer. Mutations usually oc-
cur in its helical domain (exon 9) or kinase domain (exon 
20), and the E542K, E545K, E545Q, H1047L, and H1047R 
mutations have been identified as activating mutations of 
PIK3CA 32. In addition, PIK3CA mutations have been detected 
in a small percentage (approximately 5%) of EGFR-mutated 
lung cancers with acquired resistance to EGFR-TKI therapy. 
Downstream mutations in PIK3CA are rare, but have been 
identified as a mechanism of resistance55. Recently, a study 
demonstrated that PIK3CA mutations frequently coexist with 
EGFR  or KRAS  mutations56. NSCLC patients with PIK3CA 
mutation have a poor prognosis. The role of mutant PIK3CA 
in oncogenic signaling requires further investigation, includ-
ing development of novel targets for therapeutic intervention 
in cancers harboring PIK3CA mutations.
4. BRAF
BRAF mutations are commonly detected in malignant 
melanoma: 30%–40% of cases have an activating mutation, 
whereas it is only detected in approximately 1% of NSCLC. 
The G469A, V600E, and V599E mutations in the BRAF gene 
are found in a number of tumors, including malignant mela-
noma, colorectal, and lung cancer. V599E is one of the com-
mon activating mutations and causes constitutive activation 
of the RAF/MEKL/ERK signaling cascade, resulting in pro-mi-
togenic activity and decreased drug response57. Vemurafenib 
and dabrafenib was found to be effective in treating malignant 
melanoma and are now under clinical evaluation for treating 
lung adenocarcinoma.
5. AXL
AXL belongs to the Tyro/AXL/Mer (TAM) receptor tyrosine 
kinase family and is involved in cell survival, growth, and me-
tastasis58,59. Recently, several reports have indicated that the 
aberrantly activated AXL could contribute to the development 
of acquired resistance to targeted agents such as imatinib, 
lapatinib, and erlotinib55,56,60. According to the combined work 
of three independent research groups60, in vivo xenograft and 
in vitro cell line cancer models with AXL-mediated resistance 
were established by the continued treatment with erlotinib. 
The genetic and chemical inhibition of AXL was able to re-
store sensitivity to erlotinib in these models. Furthermore, 
re-biopsy samples acquired from patients with EGFR-TKI 
resistance were found to have increased expression of AXL as 
assessed by an immunohistochemistry analysis. Although this 
evidence is quite compelling, there remain several concerns, 
such as how accurately an immunohistochemistry analysis of 
AXL expression can reflect the bypassing of AXL signal activa-
tion, which is associated with resistance. In addition, further 
study is needed to determine the exact proportion of patients 
that could benefit from the suppression of AXL signaling. Al-
though some multi-kinase inhibitors with the ability to inhibit 
AXL and several specific AXL inhibitors are under develop-
ment61, there are currently no potent selective AXL inhibitors 
available that can be used in clinical trials, which makes it dif-
ficult to confirm the exact role of AXL in acquired resistance to 
EGFR-TKI. 
Phenotype Transformation
1. Small cell transformation
Transformation of small cell lung cancer has been seldom 
observed after the development of drug resistance. Tumor 
cells with the small cell lung cancer phenotype that retain 
their original EGFR mutations are effectively treated with stan-
dard chemotherapy; however, after a period of conventional 
cytotoxic chemotherapy, these tumors become sensitized to 
EGFR-TKI. The mechanism underlying this phenomenon is 
still unknown.
2. Epithelial-mesenchymal transition
Epithelial-mesenchymal transition (EMT) is a regular physi-
ological process that occurs during embryogenesis, wound 
healing, and tissue regeneration; however, it is also observed 
in a few pathological conditions. EMT is characterized by the 
loss of E-cadherin and the gain of mesenchymal markers, such 
as vimentin and N-cadherin32. Through EMT, cancer cells 
gain mesenchymal properties and become more motile and 
invasive. Although the specific mechanism of EMT remains 
unclear, there may be several mechanisms at play during 
EMT. Activation of AXL by the PI3K/AKT pathway and loss 
of E-cadherin by activation of EGFR-MEK-ZEB1-MMP2 axis 
may induce EMT, thereby promoting cancer cell invasion and 
progression. Other EMT-inducing signals include those initi-
ated by transforming growth factor β, fibroblast growth factor, 
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epidermal growth factor, and hepatocyte growth factor, and 
pathways or factors associated with EMT include Notch, inter-
leukin 6, SOX9, FoxO4, and SRC. 
Conclusion
Through the identification of resistance mechanisms during 
EGFR-TKI treatment, new therapeutic modalities have been 
adapted for patients with unsuccessful treatments. These 
adaptations have had favorable results in some cases. Among 
them, the third generation EMSIs had outstanding therapeutic 
effects, and some of these drugs are now available for use in 
the medical field. On the other hand, inhibition of alternative 
pathways—such as MET amplification, HER2 amplification, 
PI3K/AKT/mammalian target of rapamycin signaling, and 
MAPK signaling—is theoretically sound, and many TKIs have 
been developed. However, their clinical benefit remains mod-
est, and further clinical evaluation is required. Further evalu-
ation of their biologic impact and careful selection of patients 
that would benefit from these TKIs may result in effective 
treatment of patients who were not successfully treated with 
first generation EGFR-TKI. 
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